financetom
Business
financetom
/
Business
/
Kodiak Sciences Shares Tumble After Wider-Than-Expected Q4 Loss
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Kodiak Sciences Shares Tumble After Wider-Than-Expected Q4 Loss
Mar 28, 2024 11:34 AM

02:19 PM EDT, 03/28/2024 (MT Newswires) -- Kodiak Sciences ( KOD ) shares tumbled 28% in recent Thursday trading after the company earlier reported a Q4 loss of $1.13 per diluted share, narrower than a loss of $1.35 a year earlier.

Analysts surveyed by Capital IQ expected a loss of $0.82.

As expected, no revenue for the quarter ended Dec. 31 was reported.

As of Dec. 31, the company said it had cash and cash equivalents of $285.5 million and expected to support operations through 2026.

Price: 5.40, Change: -2.05, Percent Change: -27.58

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
PRESS DIGEST- Wall Street Journal - March 20
PRESS DIGEST- Wall Street Journal - March 20
Mar 19, 2025
March 20 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. - SoftBank Group inked a deal to purchase U.S.-based chip designer Ampere Computing Holdings, a chip startup founded by Intel's ( INTC ) former president, for $6.5 billion. - U.S. President Donald...
Sanofi to acquire Dren Bio's immunology unit
Sanofi to acquire Dren Bio's immunology unit
Mar 19, 2025
(Reuters) - Sanofi on Thursday announced an agreement with biopharmaceutical company Dren Bio for the acquisition of its autoimmune disease treatment DR-0201. The French healthcare group will acquire the Dren Bio affiliate Dren-0201 for an upfront payment of $600 million and potential future payments totalling $1.3 billion, it said in a statement. The transaction is expected to close in the...
Eli Lilly launches weight-loss drug Mounjaro in India after drug regulator approval
Eli Lilly launches weight-loss drug Mounjaro in India after drug regulator approval
Mar 19, 2025
March 20 (Reuters) - Eli Lilly ( LLY ) has launched its blockbuster diabetes and weight-loss drug Mounjaro in India following approval from country's drug regulator, it said on Thursday. ...
Sodexo cuts 2025 guidance on slower growth in North America
Sodexo cuts 2025 guidance on slower growth in North America
Mar 19, 2025
(Reuters) - French food caterer Sodexo lowered its 2025 guidance on Thursday, citing slower than expected organic growth in North America. While our industry fundamentals remain strong, in North America the continued soft trend in volumes in Education and slower than expected net new ramp-up in Healthcare have impacted our ability to meet initial expectations, CEO and Chairwoman Sophie Bellon...
Copyright 2023-2026 - www.financetom.com All Rights Reserved